Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 11, 2025 08:00 ET | Source: Cerevance, Inc.

Cerevance Announces Presentations at the Alzheimer's Association International Conference 2025

AAIC Curtain Raiser
April 08, 2025 11:00 ET | Source: Cerevance, Inc.

Cerevance Presents Positive Results from Phase 1 Study of CVN293 at American Academy of Neurology 2025 Annual Meeting

CVN293 was generally well-tolerated in healthy volunteers with evidence of robust brain penetration, supporting utility of KCNK13 inhibitors for neurodegenerative diseases characterized by...
April 01, 2025 08:15 ET | Source: Cerevance, Inc.

Cerevance Presents Topline Results from Phase 2 ASCEND Trial of Solengepras as Monotherapy Treatment for Early-Stage Parkinson’s Disease at AD/PD 2025

Solengepras showed evidence of potential benefit in functional and non-motor symptoms versus placebo as measured by MDS-UPRDS Parts I, II, NMSS, and ESS, consistent with its novel non-dopaminergic...
March 27, 2025 08:00 ET | Source: Cerevance, Inc.

New Data to Be Presented at Upcoming Congresses Showcase Cerevance's Advanced Clinical Program in Parkinson’s Disease and Deep Pipeline for CNS-based Disorders

Topline results from Phase 2 ASCEND trial of solengepras as a monotherapy treatment for early-stage Parkinson’s to be presentedFirst presentation of data from Phase 1 trial of novel KCNK13 inhibitor...